ClinicalTrials.gg
Enrolling by invitationNCT06115291Updated Jun 16, 2026

Olfactory Training in Various Populations

An interventional study of Smell Test in Olfactory Disorder, Smell Disorder and Traumatic Brain Injury, sponsored by University of Kansas Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To date, there is no validated pharmacotherapy for olfactory disorders. Interestingly, olfactory training - the intentional exposure to odorants for the purposes of retraining the sense of smell - has shown success with as many as 28% of subjects over the course of 12 weeks.

Read the detailed description

Study Objectives: The overall, primary goals of these studies are as follows:

  1. To compare the outcomes of our olfactory testing battery for olfactory training to the previously published literature
  2. To determine if using a larger panel of odorants (our 15 scents versus the 4 scents previously used in the literature) yields a significant difference in olfactory recovery.
02

Conditions studied

  • Olfactory Disorder
  • Smell Disorder
  • Traumatic Brain Injury
  • Concussion, Brain
03

In context

Olfaction Disorders

70 studies on the registry are indexed under Olfaction Disorders; 18 are open to participants now.

This study's planned enrollment of 250 is above the median of 60 across 49 interventional studies indexed under Olfaction Disorders.

Browse Olfaction Disorders studies →

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80
  • Quantifiable or subjective olfactory dysfunction
  • ability to complete objective olfactory tests and comply with olfactory training protocol

Exclusion criteria

Exclusion Criteria:

  • Anyone lower than the age of 18, or greater than the age of 80
  • Pregnant women, as sinonasal symptoms and changes in smell can occur in pregnancy and are multifactorial
  • Patients with poor or questionable compliance, as participation requires daily compliance with study protocol
  • Patient's that are unable to perform routine follow-up
  • Patients who are participating in another study during this trial
  • Patients with dementia, Alzheimer's disease, Parkinson's disease, or other neurocognitive disorders, as these conditions are associated with baseline olfactory dysfunction.
  • Patients with other systemic conditions known to impact the sinonasal cavity such as Wegener's granulomatosis, Churg Strauss, and immunodeficiency, as their impact on olfaction is unknown
  • Patients who are allergic to any of the smells or components of our olfactory testing and training
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Group A: 4 scents

    Participants will be asked to inhale 4 different scents 2 times a day.

    Other: Smell Test

  • Active comparator
    Group B: 14 scents

    Participants will be asked to inhale 14 different scents 2 times a day.

    Other: Smell Test

Interventions

  • OtherSmell Test

    Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.

06

What researchers measure

Primary outcomes

  1. Olfactory Threshold

    Changes in olfactory threshold when comparing pre- and post-olfactory training for performance in terms of percent correct per specific scent and overall combination of percent correct for all tested scents

    Time frame: Change from baseline to month 6

  2. Olfactory Identification

    Changes in ability to detect and identify scents when comparing pre- and post-olfactory training for percent detected per individual scents and as a composite score reflecting performance on all scents

    Time frame: Change from baseline to month 6

Secondary outcomes

  1. Tolerance with Olfactory Training Protocol

    Self-reported tolerance with following olfactory training protocol

    Time frame: At follow-up visits

  2. Neurocognition

    Assessment of neurocognition and impact on olfactory quality of life using the Mini-Mental Status Exam (MMSE) and Montreal Cognitive Assessment (MoCA)

    Time frame: Change from baseline to month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06115291
Responsible party
David Beahm, MD (Professor, University of Kansas Medical Center) — Principal investigator
First posted
Nov 2, 2023
Start date
Feb 13, 2020
Primary completion
May 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Donald D Beahm, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion